Search results
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 1 day agoMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress PR Newswire HOUSTON ...
...Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European ...
FOX 59 Indianapolis· 2 days agoThe European Hematology Association (EHA) Hybrid Congress is the largest gathering of the hematology field in Europe ...
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology...
FOX 23 News Albany· 3 days agoUpdated data from the Phase I trial of RVU120 in patients with relapsed/refractory acute myeloid...
...Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European ...
Digital Journal· 2 days ago:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the < ...
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s...
The Kansas City Star· 4 days agoAccepted abstracts will be available on the Congress' website starting on May 14, 2024...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients...
NBC 17 Raleigh· 3 days ago(ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B have been accepted for an oral presentation and poster presentation at the 2024 ...
BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 for BI-1206 with rituximab in...
Morningstar· 3 days agoFirst data for the SC arm: 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable patients.Further updates from the IV arm; a fifth CR has been observed, ...
Q1 2024 Omeros Corp Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 1 day agoResults from the combination stage of the Phase 2 switch-over trial have been selected for a podium presentation at the Annual Congress of the European Hematology ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 18 hours agoHONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib,
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 23 hours agoMP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin Therapy (RDT): Lead DLL3 candidate advancing into
